Who will distribute Mounjaro in Korea?
By Whang, byung-woo | translator Alice Kang
24.10.10 05:48:44
가나다라
0
Market expects demand to exceed that of Saxenda... Will reorganize the obesity treatment market
Mounjaro will be released in the first half of next year…potential distribution partners under consideration
One company is in charge of distributing Trulicity …other company has experience distributing an obesity drug… Each pharmaceutical company has strengths
As Novo Nordisk's obesity drug Wegovy (semaglutide) is set to be released, the industry’s interest is on which domestic distributor Lilly will choose for its Mounjaro (tirzepatide).
▲마운자로 제품사진.
According to industry sources on the 8th, Boryung Pharmaceutical and Chong Kun Dang are in the running to become domestic distributors of Wegovy’s rival obesity drug Mounjaro.
Zuellig Pharma Korea, which handled Novo Nordisk's existing obesity drug Saxenda, was announced as the domestic distributor of Wegovy. The supply price is set at KRW 370,000 for 4 weeks’ worth.
The reason why the competition amongst domestic distributors for Mounjaro is so interesting is the sales potential of o
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)